Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 2/20 | 0.32 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932574 | 0.76 | TP53 (0.37) | TP53ALDH1A1 | |
| SCHEMBL8439081 | 0.74 | P2RX4 (0.33) | P2RX4P2RX1P2RX3P2RX7TP53 | |
| SCHEMBL10871210 | 0.74 | P2RX4 (0.33) | P2RX4P2RX1P2RX3P2RX7TP53 | |
| SCHEMBL4719320 | 0.73 | — | — | |
| SCHEMBL673948 | 0.73 | CA1 (0.33) | P2RX4P2RX1P2RX3P2RX7 | |
| SCHEMBL10824794 | 0.73 | CHRNB2 (0.38) | P2RX4P2RX1P2RX3P2RX7ALDH1A1 | |
| SCHEMBL10824792 | 0.73 | CHRNB2 (0.38) | P2RX4P2RX1P2RX3P2RX7ALDH1A1 | |
| SCHEMBL82497 | 0.71 | TSHR (0.33) | P2RX4P2RX1P2RX3P2RX7TP53 | |
| SCHEMBL42467 | 0.71 | TP53 (0.39) | P2RX4P2RX1P2RX3P2RX7TP53 | |
| SCHEMBL2334377 | 0.69 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0238883-B1 | OXABICYCLOHEPTANE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND USE | SUNTORY LIMITED (JP) | 1990-05-09 | — | — | EP | claimed |
| US-4713453-A | TREATMENT OF BRAIN DISORDERS | Suntori Limited (JP) | 1987-12-15 | — | — | US | claimed |
| EP-0238883-A1 | Oxabicycloheptane derivatives, pharmaceutical composition and use | SUNTORY LIMITED (JP) | 1987-09-30 | — | — | EP | claimed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-2939675-B1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10149840-B2 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-12-11 | — | — | US | disclosed |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2018-01-18 | — | — | US | disclosed |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO, INC. | 2016-09-22 | — | — | US | disclosed |
| EP-2533645-B1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2968220-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Agenebio, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-5143936-A | Benzopyran compound and its pharmaceutical use | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| EP-0443883-A1 | Carbapenem derivatives having antibiotic activity, their preparation and their use | Sankyo Company Limited (JP) | 1991-08-28 | — | — | EP | disclosed |
| WO-1991009017-A1 | QUINOLINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-27 | — | — | WO | disclosed |
| US-5021432-A | Hypotensive agents | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0381974-A2 | Thiophene azo dyes with a coupling component based on m-phenylene diamine | BASF Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |
| EP-0238883-B1 | OXABICYCLOHEPTANE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND USE | SUNTORY LIMITED (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4894385-A | ANTICOAGULANTS | SANKYO COMPANY LIMITED (JP) | 1990-01-16 | — | — | US | disclosed |
| EP-0339562-A1 | Benzopyran compound and its pharmaceutical use | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-11-02 | — | — | EP | disclosed |
| EP-0188383-A2 | Imidazole derivatives, their preparation and therapeutic use | SANKYO COMPANY LIMITED (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10149840-B2 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SLCO1B3, SLC22A8, SLCO4C1 | P2RX4 667/4885P2RX1 983/4885P2RX3 317/4885 |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, BACE1, GRIN2A | P2RX4 4414/4885P2RX1 4175/4885P2RX3 4293/4885 |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SLCO1B3, SLC22A8, SLCO4C1 | P2RX4 667/4885P2RX1 983/4885P2RX3 317/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | P2RX4 4414/4885P2RX1 4175/4885P2RX3 4293/4885 |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | P2RX4 4229/4885P2RX1 4240/4885P2RX3 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.